OTC Markets OTCQB - Delayed Quote USD

Therma Bright Inc. (TBRIF)

Compare
0.0350 -0.0055 (-13.58%)
At close: October 18 at 4:00 PM EDT
Loading Chart for TBRIF
DELL
  • Previous Close 0.0405
  • Open 0.0380
  • Bid 0.0354 x --
  • Ask 0.0403 x --
  • Day's Range 0.0380 - 0.0405
  • 52 Week Range 0.0040 - 0.0750
  • Volume 20,500
  • Avg. Volume 292,625
  • Market Cap (intraday) 17.127M
  • Beta (5Y Monthly) 3.07
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0100
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Therma Bright Inc. acquires, develops, manufactures, and markets proprietary healthcare and medical devices focused on respiratory diseases, vascular health, and consumer medical devices for consumer and institutional marketplace. The company's products include AcuVid, an antigen and antibody rapid screening test for COVID-19; InterceptCS, a cold sore prevention system, which provides controlled topical heat without the risk of burning the skin; Benepod, a hot and cold contrast therapy device for pain relief without pain relieving medication; Venowave, a medical compression pump designed to treat and alleviate the symptoms associated with poor circulation; and TherOZap, a thermal therapy insect device that reduces the inflammatory response, as well as relieves the symptoms of pain, itching, and inflammation associated with insect bites and stings. It also offers Inretio, a medical device for ischemic stroke treatment; Digital Cough Test (DCT), an app that uses artificial intelligence to detect multiple respiratory diseases; and inhaled statin therapy for the treatment of COVID-19 pneumonia and acute respiratory distress syndrome in hospitalized patients. The company serves consumers and medical professionals. The company was formerly known as The Jenex Corporation and changed its name to Therma Bright Inc. in February 2018. Therma Bright Inc. was incorporated in 2001 and is based in Toronto, Canada.

www.thermabright.com

--

Full Time Employees

July 31

Fiscal Year Ends

Recent News: TBRIF

View More

Research Reports: TBRIF

View More

Performance Overview: TBRIF

Trailing total returns as of 10/18/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

TBRIF
105.88%
S&P/TSX Composite index
18.44%

1-Year Return

TBRIF
5.41%
S&P/TSX Composite index
26.05%

3-Year Return

TBRIF
89.16%
S&P/TSX Composite index
18.61%

5-Year Return

TBRIF
85.23%
S&P/TSX Composite index
37.58%

Compare To: TBRIF

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: TBRIF

View More

Valuation Measures

Annual
As of 10/18/2024
  • Market Cap

    17.35M

  • Enterprise Value

    17.40M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    596.15

  • Price/Book (mrq)

    14.04

  • Enterprise Value/Revenue

    928.85

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -47.10%

  • Return on Equity (ttm)

    -174.38%

  • Revenue (ttm)

    25.84k

  • Net Income Avi to Common (ttm)

    -2.62M

  • Diluted EPS (ttm)

    -0.0100

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    99

  • Total Debt/Equity (mrq)

    4.77%

  • Levered Free Cash Flow (ttm)

    1.08M

Research Analysis: TBRIF

View More

Company Insights: TBRIF

People Also Watch